A folate metabolism-based scoring framework facilitates prognostic stratification, tumor microenvironment characterization, and prediction of immunotherapy response in ccRCC.
Abstract
Background
Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with high metastatic potential and therapeutic resistance, yet the role of folate metabolism in its pathogenesis and immune evasion remains unclear. This study aims to develop and validate a folate metabolism-related gene (FMRG) scoring system to stratify patients by prognostic risk and immune phenotypes, and to explore the functional role of key FMRGs in ccRCC progression.
Methods
Using transcriptomic and clinical data from The Cancer Genome Atlas (TCGA), we developed a folate metabolism-related gene (FMRG) scoring system via integrative machine learning and validated it in an external cohort. We analyzed associations of the FMRG score with clinicopathological features, biological pathways, immune infiltration, therapeutic responsiveness, and drug sensitivity. Single-cell RNA sequencing and spatial transcriptomics mapped candidate gene expression, and in vitro experiments validated the functional role of NGF.
Results
A ten-gene prognostic model based on the FMRG score stratified ccRCC patients into groups with distinct clinical outcomes, immune profiles, and therapeutic responses. NGF was upregulated in ccRCC, with heterogeneous spatial expression. Functional assays showed that NGF enhances proliferation, migration, and invasion.
Conclusions
This folate metabolism-based scoring framework facilitates prognostic stratification, tumor microenvironment characterization, and prediction of immunotherapy response in ccRCC. NGF is identified as a functional mediator of tumor progression, offering potential therapeutic targets and insights into metabolic-immune crosstalk.
SIRPG is identified as an immune-related prognostic hub and context-dependent tumor-cell regulator associated with apoptosis, immune communication and spatial microenvironmental organization in HNSCC.
Jiaqi Tang, Yu-Lun He, Yu-Qi Wang et al.· Frontiers in Immunology· 0 citations
This study integrates multi-omics datasets to identify candidate biomarkers that may influence TNBC progression and modulate therapeutic response and nominate CCND2 and KIF1A as candidate biomarkers and potential therapeutic targets in TNBC.
Roberto Aguilar, Victor Wang, Shane Deng· Journal of Immunology· 0 citations
RPLP0 is aberrantly upregulated in ccRCC, promoting tumor progression, migration, and invasion by facilitating the EMT process and highlighting its potential as a robust prognostic biomarker and a regulator of tumor-microenvironment interactions.
Bin Wang, Hong-Quan Liu, Yicheng Guo et al.· BMC Cancer· 0 citations
The MDrisk signature derived from mitochondrial energy metabolism and drug resistance may be useful for distinguishing prognosis, immune contexture, and computationally inferred drug susceptibility in LUAD.
Chengyang Wu, Rui Jiao, Han Yan et al.· Frontiers in Medicine· 0 citations
This study unveils 15 risk genes as potential pathogenic and therapeutic biomarkers for DLBCL and provides novel insights and targets for understanding the pathogenesis, diagnosis, and treatment of DLBCL.
FMR1 acts as a tumor suppressor in renal cancer and represents a promising pan-cancer biomarker for screening, prognostic evaluation, and immunotherapy response prediction, providing new insights for precision cancer therapy.
Huaqing Yan, Fan Xu, Xiaobo Cui et al.· Discover Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.